학술논문

Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS...
Document Type
Article
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4503-4503, 1p
Subject
Language
ISSN
0732183X